FDA OKs 1st oral drug for anaemia in adults with thalassemia
A groundbreaking oral treatment for thalassemia, Mitapivat, has received US FDA approval, offering hope for adults with this genetic blood disorder. This novel therapy targets the disease's root cause, potentially reducing the lifelong burden of blood transfusions and iron chelation.
A groundbreaking oral treatment for thalassemia, Mitapivat, has received US FDA approval, offering hope for adults with this genetic blood disorder. This novel therapy targets the disease's root cause, potentially reducing the lifelong burden of blood transfusions and iron chelation. What's Your Reaction?
